search
Back to results

the Treatment of Human Bone Marrow Mesenchymal Stem Cells in Ocular Corneal Burn

Primary Purpose

Chemical Burns

Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
human bone marrow MSC
Sponsored by
Sun Yat-sen University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chemical Burns

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. must be ocular burns including chemically burned or the thermally burned
  2. the severity degree should above the Ⅳ degree,including the Ⅳ degree(according the classification of Dua standard,2001)
  3. the subjects are willing to accept this research,and promise to coordinate with the researchers during the follow up period
  4. the subjects should abide by the laws and rules of the study.
  5. the incident time should be within 2 weeks -

Exclusion Criteria:

  1. the visual acuity is blind in any of the eye
  2. have corneal perforation or have the corneal perforation tendency
  3. have been accepted surgury on eyeball after trauma
  4. IOP≥25mmHg even after antiglaucoma
  5. have the history of other corneal diseaze or surgury
  6. have the history of radiotherapy or surgury in the eyeball
  7. associated with corneal ulcer or endoophthalmitis
  8. uncontrolled hypertension(≥150/95mmHg)
  9. abnormal liver and renal function
  10. the pregancy women -

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    human bone marrow MSC

    Arm Description

    5×106/0.5ml MSC was injected subconjunctival at the inferior fornix.If persistent epithelial defect was noted thereafter, a second AMT and MSC injection was performed.

    Outcomes

    Primary Outcome Measures

    Incidence of adverse events by subconjunctival injection of BMMSCs
    Record the adverse events, including topical complications such as ocular infection, conjunctival necrosis at the injection site, retinal artery occlusion, and systemic complications such as fever, urticaria, hemolysis, hypotension, renal and liver dysfunction, tumor formation, and/or abnormalities in complete blood counts.

    Secondary Outcome Measures

    Incidence of corneal perforation rate after subconjunctival injection of BMMSCs
    the number of corneal perforation eyes/total eyes
    Time of corneal epithelialization
    record the time when cornea finish epithelialization
    Visual acuity
    Use the visual chart to record the decimal visual acuity

    Full Information

    First Posted
    December 10, 2014
    Last Updated
    April 9, 2019
    Sponsor
    Sun Yat-sen University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02325843
    Brief Title
    the Treatment of Human Bone Marrow Mesenchymal Stem Cells in Ocular Corneal Burn
    Official Title
    The Subconjunctival Injection of Human Bone Marrow Mesenchymal Stem Cells for Ocular Corneal Burn: Prospective, Case Series Study
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2019
    Overall Recruitment Status
    Completed
    Study Start Date
    July 2015 (undefined)
    Primary Completion Date
    December 2017 (Actual)
    Study Completion Date
    December 2017 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Sun Yat-sen University

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Ocular chemical burn is one of the cause of vision loss in our country, and there are no satisfactory treatment. Human bone marrow mesenchymal stem cells (MSC) have the biological characteristics of self-renewal, immune regulation, multidirectional differentiation and tissue repair. Our preliminary research showed that in corneal alkali injury rats, the MSC can accelerated the cornea repair, inhibited angiogenesis. The aim of this study is to access the efficacy and safety of mesenchymal stem cell in the treatment of corneal burn in human.
    Detailed Description
    Corneal burn is a ocular damage disease included chemically burned and thermally burned. Surgery of corneal transplantation,amniotic membrane transplantation are some of effective,however,these therapy are expensive and the transplantation resources are limited. To arrest the inflammatory phase, several types of immunosuppressive treatments have been investigated. Corticosteroids also is important, however, long time usage of corticosteroids often cause severe side-effects. Human bone marrow mesenchymal stem cells (MSC) have the biological characteristics of self -renewal, immune regulation, multidirectional differentiation and tissue repair. Our preliminary research showed that in corneal alkali injury rats, the MSC can accelerated the cornea repair, inhibited angiogenesis. Many animal research also revealed that MSC have effect on the ocular alkali burned. And subconjunctivity injection is efficient, the clinical study of MSC on treating other disease have been developed rapidly recently, in further ,the outcome are encouraging, and no side-effect related MSC was reported, MSC can come from bone marrow, Umbilical cord blood,Adipose tissue and so on, but bone marrow MSC is mostly common used. The investigators propose to assess the efficacy and safety of human bone marrow mesenchymal stem cell in the treatment of corneal burn in human.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Chemical Burns

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    16 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    human bone marrow MSC
    Arm Type
    Experimental
    Arm Description
    5×106/0.5ml MSC was injected subconjunctival at the inferior fornix.If persistent epithelial defect was noted thereafter, a second AMT and MSC injection was performed.
    Intervention Type
    Other
    Intervention Name(s)
    human bone marrow MSC
    Intervention Description
    The arms of active comparator :human bone marrow MSC subconjunctival injection once time. If persistent epithelial defect was noted thereafter, a second MSC injection was performed.
    Primary Outcome Measure Information:
    Title
    Incidence of adverse events by subconjunctival injection of BMMSCs
    Description
    Record the adverse events, including topical complications such as ocular infection, conjunctival necrosis at the injection site, retinal artery occlusion, and systemic complications such as fever, urticaria, hemolysis, hypotension, renal and liver dysfunction, tumor formation, and/or abnormalities in complete blood counts.
    Time Frame
    6 months
    Secondary Outcome Measure Information:
    Title
    Incidence of corneal perforation rate after subconjunctival injection of BMMSCs
    Description
    the number of corneal perforation eyes/total eyes
    Time Frame
    6 months
    Title
    Time of corneal epithelialization
    Description
    record the time when cornea finish epithelialization
    Time Frame
    6 month
    Title
    Visual acuity
    Description
    Use the visual chart to record the decimal visual acuity
    Time Frame
    6 month

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    65 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: must be ocular burns including chemically burned or the thermally burned the severity degree should above the Ⅳ degree,including the Ⅳ degree(according the classification of Dua standard,2001) the subjects are willing to accept this research,and promise to coordinate with the researchers during the follow up period the subjects should abide by the laws and rules of the study. the incident time should be within 2 weeks - Exclusion Criteria: the visual acuity is blind in any of the eye have corneal perforation or have the corneal perforation tendency have been accepted surgury on eyeball after trauma IOP≥25mmHg even after antiglaucoma have the history of other corneal diseaze or surgury have the history of radiotherapy or surgury in the eyeball associated with corneal ulcer or endoophthalmitis uncontrolled hypertension(≥150/95mmHg) abnormal liver and renal function the pregancy women -
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Liang Dan, MD
    Organizational Affiliation
    Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China
    Official's Role
    Study Chair

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    22531326
    Citation
    Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol. 2012 Apr 25;12(5):383-96. doi: 10.1038/nri3209.
    Results Reference
    background
    PubMed Identifier
    3706914
    Citation
    Gao XH, Roberts A. The left triangular ligament of the liver and the structures in its free edge (appendix fibrosa hepatis) in Chinese and Canadian cadavers. Am Surg. 1986 May;52(5):246-52.
    Results Reference
    background
    PubMed Identifier
    4186059
    Citation
    Hargraves MM. Discovery of the LE cell and its morphology. Mayo Clin Proc. 1969 Sep;44(9):579-99. No abstract available.
    Results Reference
    result
    Links:
    URL
    http://www.ncbi.nlm.nih.gov/pubmed/22531326
    Description
    Multipotent mesenchymal stromal cells and the innate immune system
    URL
    http://www.ncbi.nlm.nih.gov/pubmed/23742637
    Description
    Immunoregulatory properties of clinical grade mesenchymal stromal cells: evidence, uncertainties, and clinical application
    URL
    http://www.ncbi.nlm.nih.gov/pubmed/24849741
    Description
    Modulation of the Early Inflammatory Microenvironment in the Alkali-Burned Eye by Systemically Administered Interferon-gamma-Treated Mesenchymal Stromal Cells

    Learn more about this trial

    the Treatment of Human Bone Marrow Mesenchymal Stem Cells in Ocular Corneal Burn

    We'll reach out to this number within 24 hrs